. 2021 Sep;8(9):e531-e543.

doi: 10.1016/S2352-3018(21)00108-9. Epub 2021 Jul 30.

Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Feixue Wei¹, Michael M Gaisa², Gypsyamber D'Souza³, Ningshao Xia⁴, Anna R Giuliano⁵, Stephen E Hawes⁶, Lei Gao⁷, Shu-Hsing Cheng⁸, Maria Gabriella Donà⁹, Stephen E Goldstone¹⁰, Maarten F Schim van der Loeff¹¹, Karin Neukam¹², Elissa Meites¹³, I Mary Poynten¹⁴, Jianghong Dai¹⁵, Jean-Damien Combes¹, Ulrike Wieland¹⁶, Joaquin Burgos¹⁷, Timothy J Wilkin¹⁸, Alexandra L Hernandez¹⁹, Mauricio Iribarren Díaz²⁰, Carmen Hidalgo-Tenorio²¹, Marleny Valencia Arredondo²², Alan G Nyitray²³, Nicolas Wentzensen²⁴, Eric Pf Chow²⁵, Vitaly Smelov²⁶, Rebecca G Nowak²⁷, Nittaya Phanuphak²⁸, Yin Ling Woo²⁹, Yoojin Choi³⁰, Yifei Hu³¹, Alice M Schofield³², Petra J Woestenberg³³, Admire T Chikandiwa³⁴, Andrew C Hickey³⁵, Alexandra de Pokomandy³⁶, Gad Murenzi³⁷, Hélène Péré³⁸, Marta Del Pino³⁹, Ana P Ortiz⁴⁰, Angella Charnot-Katsikas⁴¹, Xing Liu⁴², Suwat Chariyalertsak⁴³, Carol Strong⁴⁴, Jason J Ong⁴⁵, Evy Yunihastuti⁴⁶, Isabelle Etienney⁴⁷, Valentine M Ferré⁴⁸, Huachun Zou⁴⁹, Michel Segondy⁵⁰, Simbarashe Chinyowa⁵¹, Catharina J Alberts¹, Gary M Clifford⁵²

Affiliations

¹ Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
² Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁴ State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China.
⁵ Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA.
⁶ Department of Epidemiology, Department of Health Services, and Department of Global Health, University of Washington, Seattle, WA, USA.
⁷ NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁸ Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; School of Public Health, Taipei Medical University, Taipei, Taiwan.
⁹ Sexually Transmitted Infections/HIV Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
¹⁰ Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹¹ Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands; Department of Internal Medicine, Amsterdam institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
¹² Unidad Clínica de Enfermedades Infecciosas y Medicina Preventiva, UCEIMP, Instituto de Biomedicina de Sevilla, CSIC, Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Seville, Spain.
¹³ Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
¹⁴ Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
¹⁵ School of Public Health, Xinjiang Medical University, Xinjiang, Urumqi, China.
¹⁶ Institute of Virology, University of Cologne, National Reference Center for Papilloma and Polyomaviruses, Cologne, Germany.
¹⁷ Department of infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
¹⁸ Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
¹⁹ Department of Medicine, University of California, San Francisco, CA, USA; Public Health Program, College of Education and Health Sciences, Touro University, Vallejo, CA, USA.
²⁰ Department of Surgery, Complexo Hospitalario Universitario de Vigo-Hospital Álvaro Cunqueiro, Vigo, Spain.
²¹ Infectious Disease Unit, Biosanitary Research Institute Granada, University Hospital Virgen de las Nieves, Granada, Spain.
²² Universidad de Antioquia, Escuela de Microbiología, Grupo de investigación Salud Sexual y Cáncer, Medellín, Antioquia, Colombia.
²³ Clinical Cancer Center and Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, WI, USA.
²⁴ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
²⁵ Melbourne Sexual Health Centre, The Alfred Hospital, Melbourne, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
²⁶ Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France; Division of Country Health Programmes, WHO Regional Office for Europe, Copenhagen, Denmark.
²⁷ Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
²⁸ Institute of HIV Research and Innovation, Bangkok, Thailand; Center of Excellence in Transgender Health, Chulalongkorn University, Bangkok, Thailand.
²⁹ Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
³⁰ Department of Immunology, University of Toronto, Toronto, ON, Canada.
³¹ Department of Child and Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, Beijing, China.
³² Institute of Cancer Sciences, University of Manchester, Manchester, UK.
³³ Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
³⁴ Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
³⁵ Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Nonthaburi, Thailand.
³⁶ Chronic Viral Illness Service, McGill University Health Centre and Department of Family Medicine, McGill University, Montreal, QC, Canada.
³⁷ Rwanda Military Hospital and Research for Development Rwanda, Kigali, Rwanda.
³⁸ Assistance Publique Hôpitaux de Paris-Centre, Service de Microbiologie (Unité de virologie), Hôpital Européen Georges Pompidou, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Functional Genomics of Solid Tumors Laboratory, Equipe Labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, Paris, France.
³⁹ Institute Clinic of Gynecology, Obstetrics, and Neonatology, Gynecology Oncology Unit, Hospital Clínic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Medicine Faculty, Barcelona University, Barcelona, Spain.
⁴⁰ Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, USA; Graduate School of Public Health, University of Puerto Rico, San Juan, PR, USA.
⁴¹ Department of Pathology, The University of Chicago, Chicago, IL, USA; MolDx Program, Palmetto GBA, Columbia, SC, USA.
⁴² Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.
⁴³ Faculty of Public Health, Chiang Mai University and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
⁴⁴ Department of Public Health, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁴⁵ Central Clinical School, Monash University, Melbourne, VIC, Australia.
⁴⁶ Department of Internal Medicine, University of Indonesia, Jakarta, Indonesia.
⁴⁷ Proctology, Diaconesses-Croix Saint Simon Hospital, Paris, France.
⁴⁸ Université de Paris, Assistance Publique-Hôpitaux de Paris, Service de Virologie, Hôpital Bichat, Paris, France; Decision Science in Infectious Disease Prevention, Control and Care, INSERM, Université de Paris, Paris, France.
⁴⁹ Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China; School of Public Health, Shanghai Jiao Tong University, Shanghai, China; Melbourne Sexual Health Centre, Sydney, NSW, Australia.
⁵⁰ Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of Montpellier, Montpellier, France.
⁵¹ Department of Surgery, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe.
⁵² Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France. Electronic address: cliffordg@iarc.fr.

PMID: 34339628
PMCID: PMC8408042
DOI: 10.1016/S2352-3018(21)00108-9

Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Feixue Wei et al. Lancet HIV. 2021 Sep.

. 2021 Sep;8(9):e531-e543.

doi: 10.1016/S2352-3018(21)00108-9. Epub 2021 Jul 30.

Authors

Affiliations

¹ Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
² Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁴ State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China.
⁵ Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA.
⁶ Department of Epidemiology, Department of Health Services, and Department of Global Health, University of Washington, Seattle, WA, USA.
⁷ NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁸ Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; School of Public Health, Taipei Medical University, Taipei, Taiwan.
⁹ Sexually Transmitted Infections/HIV Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
¹⁰ Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹¹ Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands; Department of Internal Medicine, Amsterdam institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
¹² Unidad Clínica de Enfermedades Infecciosas y Medicina Preventiva, UCEIMP, Instituto de Biomedicina de Sevilla, CSIC, Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Seville, Spain.
¹³ Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
¹⁴ Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
¹⁵ School of Public Health, Xinjiang Medical University, Xinjiang, Urumqi, China.
¹⁶ Institute of Virology, University of Cologne, National Reference Center for Papilloma and Polyomaviruses, Cologne, Germany.
¹⁷ Department of infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
¹⁸ Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
¹⁹ Department of Medicine, University of California, San Francisco, CA, USA; Public Health Program, College of Education and Health Sciences, Touro University, Vallejo, CA, USA.
²⁰ Department of Surgery, Complexo Hospitalario Universitario de Vigo-Hospital Álvaro Cunqueiro, Vigo, Spain.
²¹ Infectious Disease Unit, Biosanitary Research Institute Granada, University Hospital Virgen de las Nieves, Granada, Spain.
²² Universidad de Antioquia, Escuela de Microbiología, Grupo de investigación Salud Sexual y Cáncer, Medellín, Antioquia, Colombia.
²³ Clinical Cancer Center and Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, WI, USA.
²⁴ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
²⁵ Melbourne Sexual Health Centre, The Alfred Hospital, Melbourne, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
²⁶ Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France; Division of Country Health Programmes, WHO Regional Office for Europe, Copenhagen, Denmark.
²⁷ Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
²⁸ Institute of HIV Research and Innovation, Bangkok, Thailand; Center of Excellence in Transgender Health, Chulalongkorn University, Bangkok, Thailand.
²⁹ Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
³⁰ Department of Immunology, University of Toronto, Toronto, ON, Canada.
³¹ Department of Child and Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, Beijing, China.
³² Institute of Cancer Sciences, University of Manchester, Manchester, UK.
³³ Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
³⁴ Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
³⁵ Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Nonthaburi, Thailand.
³⁶ Chronic Viral Illness Service, McGill University Health Centre and Department of Family Medicine, McGill University, Montreal, QC, Canada.
³⁷ Rwanda Military Hospital and Research for Development Rwanda, Kigali, Rwanda.
³⁸ Assistance Publique Hôpitaux de Paris-Centre, Service de Microbiologie (Unité de virologie), Hôpital Européen Georges Pompidou, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Functional Genomics of Solid Tumors Laboratory, Equipe Labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, Paris, France.
³⁹ Institute Clinic of Gynecology, Obstetrics, and Neonatology, Gynecology Oncology Unit, Hospital Clínic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Medicine Faculty, Barcelona University, Barcelona, Spain.
⁴⁰ Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, USA; Graduate School of Public Health, University of Puerto Rico, San Juan, PR, USA.
⁴¹ Department of Pathology, The University of Chicago, Chicago, IL, USA; MolDx Program, Palmetto GBA, Columbia, SC, USA.
⁴² Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.
⁴³ Faculty of Public Health, Chiang Mai University and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
⁴⁴ Department of Public Health, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁴⁵ Central Clinical School, Monash University, Melbourne, VIC, Australia.
⁴⁶ Department of Internal Medicine, University of Indonesia, Jakarta, Indonesia.
⁴⁷ Proctology, Diaconesses-Croix Saint Simon Hospital, Paris, France.
⁴⁸ Université de Paris, Assistance Publique-Hôpitaux de Paris, Service de Virologie, Hôpital Bichat, Paris, France; Decision Science in Infectious Disease Prevention, Control and Care, INSERM, Université de Paris, Paris, France.
⁴⁹ Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China; School of Public Health, Shanghai Jiao Tong University, Shanghai, China; Melbourne Sexual Health Centre, Sydney, NSW, Australia.
⁵⁰ Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of Montpellier, Montpellier, France.
⁵¹ Department of Surgery, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe.
⁵² Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France. Electronic address: cliffordg@iarc.fr.

PMID: 34339628
PMCID: PMC8408042
DOI: 10.1016/S2352-3018(21)00108-9

Abstract

Background: Robust age-specific estimates of anal human papillomavirus (HPV) and high-grade squamous intraepithelial lesions (HSIL) in men can inform anal cancer prevention efforts. We aimed to evaluate the age-specific prevalence of anal HPV, HSIL, and their combination, in men, stratified by HIV status and sexuality.

Methods: We did a systematic review for studies on anal HPV infection in men and a pooled analysis of individual-level data from eligible studies across four groups: HIV-positive men who have sex with men (MSM), HIV-negative MSM, HIV-positive men who have sex with women (MSW), and HIV-negative MSW. Studies were required to inform on type-specific HPV infection (at least HPV16), detected by use of a PCR-based test from anal swabs, HIV status, sexuality (MSM, including those who have sex with men only or also with women, or MSW), and age. Authors of eligible studies with a sample size of 200 participants or more were invited to share deidentified individual-level data on the above four variables. Authors of studies including 40 or more HIV-positive MSW or 40 or more men from Africa (irrespective of HIV status and sexuality) were also invited to share these data. Pooled estimates of anal high-risk HPV (HR-HPV, including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and HSIL or worse (HSIL+), were compared by use of adjusted prevalence ratios (aPRs) from generalised linear models.

Findings: The systematic review identified 93 eligible studies, of which 64 contributed data on 29 900 men to the pooled analysis. Among HIV-negative MSW anal HPV16 prevalence was 1·8% (91 of 5190) and HR-HPV prevalence was 6·9% (345 of 5003); among HIV-positive MSW the prevalences were 8·7% (59 of 682) and 26·9% (179 of 666); among HIV-negative MSM they were 13·7% (1455 of 10 617) and 41·2% (3798 of 9215), and among HIV-positive MSM 28·5% (3819 of 13 411) and 74·3% (8765 of 11 803). In HIV-positive MSM, HPV16 prevalence was 5·6% (two of 36) among those age 15-18 years and 28·8% (141 of 490) among those age 23-24 years (p_trend=0·0091); prevalence was 31·7% (1057 of 3337) among those age 25-34 years and 22·8% (451 of 1979) among those age 55 and older (p_trend<0·0001). HPV16 prevalence in HIV-negative MSM was 6·7% (15 of 223) among those age 15-18 and 13·9% (166 of 1192) among those age 23-24 years (p_trend=0·0076); the prevalence plateaued thereafter (p_trend=0·72). Similar age-specific patterns were observed for HR-HPV. No significant differences for HPV16 or HR-HPV were found by age for either HIV-positive or HIV-negative MSW. HSIL+ detection ranged from 7·5% (12 of 160) to 54·5% (61 of 112) in HIV-positive MSM; after adjustment for heterogeneity, HIV was a significant predictor of HSIL+ (aPR 1·54, 95% CI 1·36-1·73), HPV16-positive HSIL+ (1·66, 1·36-2·03), and HSIL+ in HPV16-positive MSM (1·19, 1·04-1·37). Among HPV16-positive MSM, HSIL+ prevalence increased with age.

Interpretation: High anal HPV prevalence among young HIV-positive and HIV-negative MSM highlights the benefits of gender-neutral HPV vaccination before sexual activity over catch-up vaccination. HIV-positive MSM are a priority for anal cancer screening research and initiatives targeting HPV16-positive HSIL+.

Funding: International Agency for Research on Cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ARG received travel fees from Merck & Co to participate in scientific advisory board meetings, and her institution has received grants for research from Merck & Co. SEH is funded by the US National Institutes of Health and the Bill & Melinda Gates Foundation outside the submitted work; and is a consultant for In Bios and a grant reviewer for US National Institutes of Health Study Section outside the submitted work. SEG received an investigator-initiated grant from Merck & Co, Inovio, and Medtronic outside the submitted work; consulting fees from THD America outside the submitted work; and payment as a speaker and financial support for attending meetings from Merck & Co outside the submitted work. MFSvdL received funds awarded to his institution from the AidsFonds charity and from Merck Sharpe & Dohme for participation on a data safety monitoring board or advisory board. KN is the recipient of a Miguel Servet research grant (CPII18/00033) from the Instituto de Salud Carlos III (Madrid, Spain) outside the submitted work. AGN received an investigator-initiated grant from Merck & Co in 2010–11 awarded to his institution at the time (Moffitt Cancer Center, Tampa, FL, USA) to assess the prevalence and incidence of anal HPV among men, allowing genotyping of samples (these data are included in the current Article); received travel fees from EUROGIN to present at their conferences; and received donated swabs and vials from COPAN. UW received grant support from the German Federal Ministry of Health for a study included in this report. EPFC is supported by an Australian National Health and Medical Research Council Emerging Leadership Investigator Grant (GNT1172873) outside the submitted work. YC received financial support from the Canadian Institutes of Health Research scholarship/studentship (CGS-D) outside the submitted work. YH received funding from the Natural Science Foundation of China International/Regional Research Collaboration Project (72061137007) and the Natural Science Foundation of China (81673232 and 82073574) outside the submitted work. GM received funding from US National Institutes of Health/National Cancer Institute outside the submitted work. APO received funds awarded to her institution from Aids Malignancy Consortium (2UM1CA121947–14) outside the submitted work; funds awarded to her institution from California-Mexico-Puerto Rico Partnership Center for Prevention of HPV-related Cancer in HIV-positive Populations (5U54CA242646–02) and from UPR/MDACC: Partnership for Excellence in Cancer Research (5U54-CA096297–17 and 5R21DE027226–02) outside the submitted work; and consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, and educational events from Merck & Co outside the submitted work. HZ received funding awarded to Sun Yat-sen University from the Natural Science Foundation of China Excellent Young Scientists Fund (82022064), the Natural Science Foundation of China International/Regional Research Collaboration Project (72061137001), and the Precision Targeted Intervention Studies among High Risk Groups for HIV Prevention in China, National Science and Technology Major Project of China (2018ZX10721102) outside the submitted work. All other authors declare no competing interests.

Figures

**Figure 1**
Study selection All studies included in this pooled analysis were mutually exclusive. HPV=human papillomavirus. MSM=men who have sex with men. MSW=men who have sex with women. *The authors of these studies did not share individual-level data. †Included five HIV-positive MSM and one HIV-positive MSW. ‡Included 247 HIV-positive MSM, 278 HIV-negative MSM, one HIV-positive MSW, and seven HIV-negative MSW.

**Figure 2**
Prevalence of type-specific and grouped type HPV infection in four male risk groups HR-HPV includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Error bars show 95% CIs. HPV=human papillomavirus. 2v-HPV=HPV16 and 18. 4v-HPV=HPV6, 11, 16, and 18. 9v-HPV=HPV6, 11, 16, 18, 31, 33, 45, 52, and 58. HR-HPV=high-risk HPV. MSW=men who have sex with women. MSM=men who have sex with men.

**Figure 3**
Age-specific prevalence of HPV16 (A) and HR-HPV (B) infection in four male risk groups Error bars show 95% CIs. PRs were adjusted for study. HR-HPV includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV=human papillomavirus. HR-HPV=high-risk HPV. MSM=men who have sex with men. MSW=men who have sex with women. aPR=adjusted prevalence ratio. *Significant aPRs relative to the reference group.

**Figure 4**
Overall and age-specific proportion of men infected with HPV16 and other HR-HPV types HR-HPV includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV=human papillomavirus. HR-HPV=high-risk HPV. MSM=men who have sex with men. MSW=men who have sex with women.

**Figure 5**
Prevalence of anal HSIL+ All men included in this analysis had anal cytology results. Studies are ranked in descending order of anal HSIL+ prevalence among HIV-positive MSM, stratified by diagnostic strategy. HPV=human papillomavirus. HRA=high-resolution anoscopy. HSIL+=high-grade squamous intraepithelial lesions or worse. MSM=men who have sex with men. *Only includes participants with HSIL+ plus HPV16-positive swabs.

**Figure 6**
Prevalence of anal HPV16 infection and anal HSIL+ PRs were adjusted for age group and study. Error bars show 95% CIs. aPR=adjusted prevalence ratio. HPV=human papillomavirus. HSIL+=high-grade squamous intraepithelial lesions or worse. MSM=men who have sex with men. *Significant aPRs relative to the reference group. †Only includes participants with HSIL+ plus HPV16-positive swabs.

See this image and copyright information in PMC

Comment in

Advancing anal cancer prevention in men.
Burchell AN, Grennan T. Burchell AN, et al. Lancet HIV. 2021 Sep;8(9):e522-e523. doi: 10.1016/S2352-3018(21)00149-1. Epub 2021 Jul 30. Lancet HIV. 2021. PMID: 34339629 No abstract available.

References

1. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–670. - PMC - PubMed
1. Clifford GM, Georges D, Shiels MS. A meta-analysis of anal cancer incidence by risk group: towards a unified anal cancer risk scale. Int J Cancer. 2021;148:38–47. - PMC - PubMed
1. Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol. 2017;46:924–938. - PubMed
1. Shiels MS, Pfeiffer RM, Chaturvedi AK, Kreimer AR, Engels EA. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst. 2012;104:1591–1598. - PMC - PubMed
1. Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18:198–206. - PMC - PubMed

Uncited References

1. Medina-Laabes DT, Suarez-Perez EL, Guiot HM. Human papillomavirus correlates with histologic anal high-grade squamous intraepithelial lesions in Hispanics with HIV. J Low Genit Tract Dis. 2018;22:320–325. - PMC - PubMed
1. Machalek DA, Poynten IM, Jin F. A composite cytology-histology endpoint allows a more accurate estimate of anal high-grade squamous intraepithelial lesion prevalence. Cancer Epidemiol Biomarkers Prev. 2016;25:1134–1143. - PubMed
1. Hernandez AL, Efird JT, Holly EA, Berry JM, Jay N, Palefsky JM. Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco. J Acquir Immune Defic Syndr. 2013;63:532–539. - PMC - PubMed
1. de Pokomandy A, Rouleau D, Ghattas G. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199:965–973. - PubMed
1. Clarke MA, Cheung LC, Lorey T. Five-year prospective evaluation of cytology, HPV testing, and biomarkers for detection of anal precancer in HIV+ MSM. Clin Infect Dis. 2018;69:631–638. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Affiliations

Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

References

Uncited References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous